reason report
focu pt
bottom line repres attract turnaround stori
compel valuat view one favorit
large-cap pick revenue growth acceler
look set start take form meaning way within
next qtr current level -- -one cheapest among large-cap
med-tech -- -we think multipl gradual move higher given
clear path revenue growth acceler margin improv higher
ep growth move past suppli issu new
cementless knee qtr perform management expect
earlier-than-plan return org cc revenue growth increas
confid upward estim revis bia toward above-street
out-year estim higher pt goe vs prior
assum higher multipl appli adj ep -- -reflect
increas confid ep growth acceler prospect
org y/i cc growth beat acceler ep beat
cc org revenue growth estimate cc sell day adj
our/consensu cc org knee set outperform
hip dental in-lin spine cmf under-perform
ww knee y/i cc deliv upsid vs us/consensu
follow ww set cc us knee rep cc vs
beat think revers trend neg growth
 ww spine cmf cc underperform
due difficult comp bone cement continu drag
 gm consensu ebita
margin street due sales/gm
upsid togeth ep beat
deliv best ww cc knee perform
year help somewhat initi rosa knee capit
contribut mostli due acceler us core knee implant
growth narrow gap vs market rate management
quantifi rosa knee capit sale say
rel small even exclud capit core us knee growth
still acceler aid recent product launch persona
cementless sale forc slowli gain confid
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
cash ep
year price history/av daili volume mil
compani inform svb leerink llc research
million ep ex-amort
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
estim core us knee growth tougher y/i
comp vs model us knee
growth acceler continu close gap
market rate core implant base higher level robot capit
placement -- -over time grow robot instal base continu
gener increas implant revenue momentum well model
us knee growth vs inclus robot capit
contribut think estim could conserv
revenue outlook inch higher low end management expect
achiev y/i cc revenue growth in-lin wtd average market rate
month earlier expect report revenue growth
expect flat y/i vs y/i prior
contempl steeper fx headwind vs
prior organ cc growth full-year sell
day impact posit bill day benefit slightli
almost fulli revers neg headwind neg
impact given progress made turnaround
activ ytd management increas confid abil deliv
goal wamgr start encourag
management will put stake ground floor model
cc cc sell day cc cc sell day
cc vs cc growth
cadenc perspect cc like
higher vs face tougher y/i comp well
sell day benefit improv busi momentum
look capabl power tougher comp
ebita margin tighten opex increas ep outlook
increas low end rev/low tax gm expect step
vs remain pressur adj
ebita margin inch lower high end vs
prior due increas invest robot d/commerci
confid level op margin expans
ultim adj ep guidanc increas vs
prior adj tax rate expect vs
rosa knee still limit launch feedback posit
meanwhil rosa spine launch delay earli management
indic rosa knee surgeon feedback posit
construct feedback center around training/educ
result increas invest improv area
respect rosa spine launch push system
need enhanc around instrument readi
prime time management also indic want focu mfg resources/
capac rosa knee near-term ensur success full-
scale launch spine applic take back seat
least
rate zimmer hold nyse outperform pt view strong
turnaround stori make new leadership think compani improv
execut eventu drive faster ep growth compani come side
manufactur suppli recoveri post re-acceler top line given potenti
may even begin engag portfolio re-shap beyond
shift exposur toward faster-grow end-mkts/subseg end day
gener solid hold market-lead posit across key orthoped market
favor demograph tailwind trade signific price-to-earnings discount large-
cap med-tech think zbh steep discount vs peer narrow compani improv
execut eventu drive faster ep growth
trade fairli steep discount large-cap med-tech group price-to-earnings average
believ level discount vs large-cap peer warrant given average top-lin growth
execut risk relat zbh-biomet integr suppli issu think current
discount vs peer wide believ ultim busi time
capabl gener hsd ep growth gradual top-lin acceler low- mid-
singl digit growth territori pt assum trade
ep narrow valuat gap vs large-cap med-tech average
forward multipl would zbh current price-to-earnings multipl would still repres
discount large-cap exclud ew group average price-to-earnings
compani large-cap group includ alc
risk valuat includ abl execut post-biomet ldrh deal
synergi guidanc take longer address suppli issu build safeti
stock inventori -- -which could limit co abil meet demand and/or regain market share futur
qtr crucial sale growth acceler stori underli ortho recon growth
rate slow vs current expect level price eros industri ortho recon price
occur dramat pace expect wors steadi y/i declin
rang unabl off-set asp price declin posit mix benefit relat new
product offer could hinder long-term share price appreci
robot total knee categori begin acceler faster-than-expect and/or abl
capit rosa knee applic time fashion fda approv
million except ep
compani report streetaccount consensu svb leerink llc research
million except ep
compani report svb leerink llc estim
report number look modest
report number look modest
report number look modest
 impress
 impress
 impress
weight particularli
weight particularli
estim
estim
estim
sell day impact rel neutral
sell day impact rel neutral
sell day impact rel neutral
full-year day headwind
full-year day headwind
full-year day headwind
roughli off-set
impact spread fairli evenli
roughli off-set
impact spread fairli evenli
major
major
benefit realiz
benefit realiz
roughli off-set
slightli higher vs fx
slightli higher vs fx
qtrli cadenc declin throughout yr
compani cont reduc debt level
qtrli cadenc declin throughout yr
compani cont reduc debt level
qtrli cadenc declin throughout yr
compani cont reduc debt level
incl potenti payment
previous disclos patent litig
incl potenti payment
previous disclos patent litig
incl potenti payment
previous disclos patent litig
ex item would
ex item would
ex item would
major pay debt
achiev leverag goal
major pay debt
achiev leverag goal
major pay debt
achiev leverag goal
compani report svb leerink llc estim
dollar million except per share data
product sold ex-intang amort
research develop expens
sell gener administr expens
income/ loss attribut non-controlling
adj dilut averag share million
gross margin ex devic tax
oper expens sale
sg sale
 sale
compani data svb leerink llc estim
note restat certain incom statement item reflect adopt account standard updat revenu contract custom topic account standard updat
dollar million
total sale adjust divestitur
dollar million
compani report svb leerink llc estim
